Annual Drug Patent Expirations for OLUMIANT
Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from one supplier. There are five patents protecting this drug.
Drug patent litigation for OLUMIANT.
This drug has eigthy-nine patent family members in forty-four countries.
The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
